Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
The Silent Struggle of HIV Treatment Adherence

Long-acting antiretroviral medications has the potential to help many people with HIV who face adherence barriers to better health. But that does not mean that it will be a panacea for all adherence issues.

Published
28 August 2015
From
The Body
European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company’s Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg (R/F/TAF) has been fully validated and is now under evaluation by the European Medicines Agency (EMA).

Published
21 August 2015
From
Gilead press release
'Tweezer' molecule can block HIV in semen, study says

A US-German team of scientists has successfully tested a tweezer-shaped molecule which can be effective in preventing HIV transmission. CLR01 is effective in HIV prevention as it blocks the activity of special polymers in semen called ‘amyloid fibrils’ which enhance HIV infectivity as the virus attaches to the membranes of human cells with the help of this structure. The “molecule tweezer” can disrupt fibril formation as well as disassemble those already formed. The molecule can also target the virus itself by destroying its membrane. At the same time CLR01 does not affect the membranes of other cells which makes it safe to use.

Published
19 August 2015
From
RT.com
Medicines Patent Pool At 5 Years: Promises Kept, Changes Ahead – An Interview With Greg Perry

The Medicines Patent Pool in Geneva is celebrating five years of existence this month. MPP Executive Director Greg Perry sat down with Intellectual Property Watch Catherine Saez to describe progress made since its inception, the success of its licensing agreement model, and plans for the future, including a possible extension to other diseases such as tuberculosis and hepatitis C.

Published
04 August 2015
From
Intellectual Property Watch
GSK flags up pipeline as HIV drugs help it beat profit forecasts

GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts.

Published
30 July 2015
From
Reuters
Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health

People who switch from the current version of tenofovir to tenofovir alafenamide (TAF) – a new formulation that reaches higher levels in HIV-infected cells – maintained undetectable

Published
28 July 2015
By
Liz Highleyman
New NNRTI doravirine suppresses HIV as well as efavirenz but with fewer central nervous system side-effects

Merck's next-generation NNRTI doravirine (formerly known as MK-1439) was found to be as effective as efavirenz at suppressing HIV replication, but half as many study participants taking doravirine experienced drug-related

Published
23 July 2015
By
Liz Highleyman
Next-generation maturation inhibitor BMS-955176 shows good antiviral activity in combination with atazanavir

The next-generation HIV maturation inhibitor BMS-955176 was well-tolerated and suppressed HIV viral load as well as standard antiretroviral therapy when used in a combination with atazanavir (Reyataz)

Published
22 July 2015
By
Liz Highleyman
Targets proliferate in HIV cure research

The Towards an HIV Cure two-day symposium has become a fixture in advance of the International AIDS Society conferences and this one featured a more varied range

Published
21 July 2015
By
Gus Cairns
New drug holds out promise of long-term control or even cure of HIV

Scientists at the Scripps Research Institute in California have discovered a new type of drug that may permanently inhibit HIV from becoming reactivated in the cells that

Published
18 July 2015
By
Gus Cairns
← First12345...84Next →

Filter by country